Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) Sees Significant Growth in Short Interest

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) saw a large growth in short interest in June. As of June 15th, there was short interest totaling 65,485 shares, a growth of 95.9% from the May 31st total of 33,421 shares. Currently, 0.1% of the shares of the stock are short sold. Based on an average daily volume of 64,658 shares, the short-interest ratio is currently 1.0 days.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on NBTX shares. UBS Group upped their target price on shares of Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. TD Cowen reissued a “buy” rating on shares of Nanobiotix in a research note on Thursday, March 12th. Weiss Ratings restated a “sell (d-)” rating on shares of Nanobiotix in a research report on Tuesday, April 21st. Leerink Partners upped their price objective on shares of Nanobiotix from $37.00 to $46.00 and gave the company an “outperform” rating in a research note on Thursday, June 4th. Finally, HC Wainwright reiterated a “buy” rating on shares of Nanobiotix in a report on Monday, May 18th. Four analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Nanobiotix currently has a consensus rating of “Moderate Buy” and an average price target of $37.33.

Institutional Trading of Nanobiotix

Several hedge funds have recently made changes to their positions in the company. Millennium Management LLC acquired a new position in Nanobiotix in the fourth quarter valued at approximately $390,000. Marshall Wace LLP purchased a new stake in Nanobiotix in the fourth quarter valued at $220,000. Finally, Royal Bank of Canada raised its position in Nanobiotix by 2,000.0% in the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock valued at $61,000 after purchasing an additional 2,500 shares during the period. Hedge funds and other institutional investors own 38.81% of the company’s stock.

Nanobiotix Stock Down 2.7%

NASDAQ:NBTX traded down $1.08 during trading hours on Thursday, hitting $38.40. The company had a trading volume of 94,515 shares, compared to its average volume of 63,122. Nanobiotix has a 1 year low of $4.79 and a 1 year high of $57.14. The company has a 50-day moving average of $38.82 and a 200 day moving average of $30.84.

Nanobiotix (NASDAQ:NBTX) last posted its quarterly earnings results on Sunday, February 15th. The company reported ($0.23) EPS for the quarter. The firm had revenue of $3.42 million during the quarter. On average, research analysts expect that Nanobiotix will post 0.19 earnings per share for the current year.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.